Fractionated radiotherapy for surgically resected intracranial meningiomas: a multicentre retrospective cohort study.

[1]  A. Nowacki,et al.  Adjuvant radiation versus observation with salvage radiation after gross-total resection of WHO grade II meningiomas: a propensity score-adjusted analysis. , 2021, Journal of Neurosurgery.

[2]  R. Beroukhim,et al.  A molecularly integrated grade for meningioma , 2021, Neuro-oncology.

[3]  Lydia Y. Liu,et al.  A clinically applicable integrative molecular classification of meningiomas , 2021, Nature.

[4]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[5]  M. Weller,et al.  EANO guideline on the diagnosis and management of meningiomas. , 2021, Neuro-oncology.

[6]  B. Lhermitte,et al.  High risk of recurrence for grade II meningioma: a 10-year multicenter analysis of prognosis factors. , 2021, Chinese clinical oncology.

[7]  A. Niemierko,et al.  Timing of Adjuvant Radiotherapy in Atypical Meningiomas , 2020 .

[8]  Mark W. Youngblood,et al.  Associations of Meningioma Molecular Subgroup and Tumor Recurrence. , 2020, Neuro-oncology.

[9]  Q. Wei,et al.  Molecular Mechanism and Approach in Progression of Meningioma , 2020, Frontiers in Oncology.

[10]  D. Munoz,et al.  Necrosis and Brain Invasion Predict Radio-Resistance and Tumor Recurrence in Atypical Meningioma: A Retrospective Cohort Study. , 2020, Neurosurgery.

[11]  A. Niemierko,et al.  Adjuvant radiotherapy versus surveillance following surgical resection of atypical meningiomas. , 2020, International journal of radiation oncology, biology, physics.

[12]  David T. W. Jones,et al.  CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas , 2020, Acta Neuropathologica.

[13]  Gerrit Hirschfeld,et al.  cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R , 2020, J. Stat. Softw..

[14]  V. Budach,et al.  Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma , 2019, Radiation Oncology.

[15]  M. Erçin,et al.  Interobserver Variability in Mitotic Count for Meningioma Grading: How Can We Reduce It? , 2019, Turkish neurosurgery.

[16]  John F. Magnotti,et al.  Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors , 2019, Proceedings of the National Academy of Sciences.

[17]  Raymond Y Huang,et al.  DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. , 2019, Neuro-oncology.

[18]  J. Suh,et al.  A management dilemma: adjuvant radiotherapy after gross total resection of atypical meningioma , 2019, Translational Cancer Research.

[19]  Arie Perry,et al.  Molecular and translational advances in meningiomas. , 2019, Neuro-oncology.

[20]  I. Dunn,et al.  Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma , 2019, Cancer medicine.

[21]  B. Coche-Déquéant,et al.  Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control , 2018, Scientific Reports.

[22]  S. Kannan,et al.  Impact of timing of radiation therapy on outcomes in atypical meningioma: A clinical audit. , 2018, Practical radiation oncology.

[23]  C. Tsien,et al.  Radiologic Response and Disease Control of Recurrent Intracranial Meningiomas Treated With Reirradiation. , 2018, International journal of radiation oncology, biology, physics.

[24]  Raymond Y Huang,et al.  Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. , 2018, Neuro-oncology.

[25]  C. Apra,et al.  Current treatment options for meningioma , 2018, Expert review of neurotherapeutics.

[26]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[27]  G. Bauman,et al.  Lessons learned from reirradiation of recurrent skull base meningioma: A case report and review of the literature , 2017, Advances in radiation oncology.

[28]  M. Mehta,et al.  High-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. , 2016, International journal of radiation oncology, biology, physics.

[29]  M. Weller,et al.  EANO guidelines for the diagnosis and treatment of meningiomas. , 2016, The Lancet. Oncology.

[30]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[31]  K. Aldape,et al.  TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.

[32]  M. Boakye,et al.  Patterns of Care and Outcomes of Adjuvant Radiotherapy for Meningiomas: A Surveillance, Epidemiology, and End Results and Medicare Linked Analysis , 2016, Cureus.

[33]  C. Gamble,et al.  The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial , 2015, Trials.

[34]  D. Brachman,et al.  Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. , 2015, Journal of neurosurgery.

[35]  Mark D. Johnson,et al.  Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. , 2014, Neuro-oncology.

[36]  M. Jenkinson,et al.  Radiotherapy versus observation following surgical resection of atypical meningioma (the ROAM trial). , 2014, Neuro-oncology.

[37]  Justus J. Randolph,et al.  A Step-by-Step Guide to Propensity Score Matching in R , 2014 .

[38]  C. James,et al.  Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. , 2014, Neuro-oncology.

[39]  J. Sherman,et al.  A Review of Stereotactic Radiosurgery Practice in the Management of Skull Base Meningiomas , 2014, Journal of Neurological Surgery—Part B.

[40]  James J. Evans,et al.  Reirradiation of recurrent meningioma , 2012, Journal of Clinical Neuroscience.

[41]  A. von Deimling,et al.  Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. , 2011, International journal of radiation oncology, biology, physics.

[42]  Joseph Wiemels,et al.  Epidemiology and etiology of meningioma , 2010, Journal of Neuro-Oncology.

[43]  S. Naqvi,et al.  Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. , 2004, International journal of radiation oncology, biology, physics.

[44]  T. Solberg,et al.  Radiosurgery and stereotactic radiotherapy for intracranial meningiomas. , 2003, Neurosurgical focus.

[45]  OUP accepted manuscript , 2021, Neuro-Oncology.

[46]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.

[47]  S. Short,et al.  Controversies in radiotherapy for meningioma. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[48]  Thomas Backer-Grøndahl,et al.  The histopathological spectrum of human meningiomas. , 2012, International journal of clinical and experimental pathology.

[49]  N. Saito,et al.  Role of Gamma Knife Radiosurgery in Neurosurgery: Past and Future Perspectives , 2010 .

[50]  A. Sarkar,et al.  Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas. , 2009, Otolaryngologic clinics of North America.

[51]  E. B. Butler,et al.  Malignant meningioma: An indication for initial aggressive surgery and adjuvant radiotherapy , 2004, Journal of Neuro-Oncology.